3,654,920 Shares in Enanta Pharmaceuticals, Inc. $ENTA Purchased by Jupiter Topco LLC

Jupiter Topco LLC purchased a new stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,654,920 shares of the biotechnology company’s stock, valued at approximately $53,252,000. Jupiter Topco LLC owned about 12.55% of Enanta Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in Enanta Pharmaceuticals during the 2nd quarter worth approximately $47,304,000. Janus Henderson Group PLC boosted its stake in shares of Enanta Pharmaceuticals by 91.6% during the 4th quarter. Janus Henderson Group PLC now owns 3,729,659 shares of the biotechnology company’s stock valued at $58,761,000 after buying an additional 1,782,745 shares during the last quarter. ADAR1 Capital Management LLC purchased a new position in shares of Enanta Pharmaceuticals during the 2nd quarter valued at approximately $19,603,000. Spruce Street Capital LP purchased a new position in shares of Enanta Pharmaceuticals during the 2nd quarter valued at approximately $15,873,698,000. Finally, Krensavage Asset Management LLC grew its position in shares of Enanta Pharmaceuticals by 30.8% during the fourth quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock worth $43,626,000 after buying an additional 651,946 shares in the last quarter. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Stock Down 2.5%

Shares of NASDAQ ENTA opened at $13.80 on Friday. The stock’s 50 day moving average price is $13.57 and its two-hundred day moving average price is $13.48. Enanta Pharmaceuticals, Inc. has a 52-week low of $7.05 and a 52-week high of $17.15. The stock has a market capitalization of $401.86 million, a P/E ratio of -5.73 and a beta of 0.98.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, August 10th. The biotechnology company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.16). Enanta Pharmaceuticals had a negative return on equity of 61.84% and a negative net margin of 96.89%.The firm had revenue of $14.36 million during the quarter, compared to analyst estimates of $16.76 million. On average, analysts anticipate that Enanta Pharmaceuticals, Inc. will post -2.36 EPS for the current year.

Wall Street Analyst Weigh In

ENTA has been the subject of a number of research analyst reports. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Enanta Pharmaceuticals in a research note on Tuesday, June 23rd. Wall Street Zen downgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 22nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Friday, July 17th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $19.50.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct?acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.